About US
Contact us
-
Lilly settles suit linking old miscarriage drug to breast cancerThe first court fight over the old miscarriage drug DES and alleged links to breast cancer didn't last long. On the second day of the trial, Eli Lilly ($LLY) settled with the four plaintiffs, who had2013/1/11
-
FDA orders dosage cuts on Sanofi's Ambien and its relativesWhat's one of the FDA's biggest worries about sleeping-pill safety? Hint: It's not your usual sort of adverse event. It's more like a bank shot off the human body than a hit to the body itself: Auto2013/1/11
-
Is rumored pharma target Bausch + Lomb aiming for an IPO instead?Big Pharma CEOs are throwing cold water on expectations for more medium-sized M&A this year. While analysts see promise for $10 billion deals, executives from Novartis ($NVS) to the newly indepen2013/1/10
-
Swiss insurer jumps into legal fight over Bayer's YasminBayer has another foe in its battle to defend the contraceptive pill Yasmin. Switzerland's biggest insurer, CSS, is backing a woman's claims against the German company, joining in her lawsuit that al2013/1/10
-
China hits Big Pharma meds with 15%-plus price cutsPharma's path to a big payoff in China is growing narrower and narrower. The government has just announced its fourth drug-price cut since 2011, with 400 meds subject to forced discounts. And on that2013/1/9
-
Ethris Announces Research Based Alliance on SNIM® Modified RNA with ShireEthris GmbH and Shire today announce the initiation of a research based alliance focused on the development and commercialization of novel RNA-based therapeutics. Many devastating human diseases2013/1/9
-
Roche chairman pooh-poohs another Illumina bidIf you've been rooting for Roche ($RHHBY) to make another run at the gene sequencing company Illumina ($ILMN), you could be in for a disappointment. The drugmaker's chairman, Franz Humer, told a Swis2013/1/8
-
Takeda, Affymax nail supply deal for Omontys anemia drugTakeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to tre2013/1/8
-
Evotec Acquires Cell Culture ServiceEvotec AG has acquired Cell Culture Service GmbH (CCS), based in Hamburg, Germany, for $1.5 million in cash and an earn-out payment of $1.4 million in cash. CCS supplies custom cells and cell-based r2013/1/7
-
NGM, Janssen in Diabetes Discovery AllianceNGM Biopharmaceuticals has signed a worldwide agreement with Janssen Pharmaceuticals to discover and develop therapeutics for the potential treatment of Type 2 diabetes and other metabolic diseases.2013/1/7